All In Biotech

Drug Trial Radar · NCT06687369

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Combination With Chemotherapy for the Treatment of Patients With Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 726 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

726

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Aug 31, 2026

Study completion Sep 2027

Sponsor

Lead sponsor
mAbxience Research S.L.Industry
Sponsor type
Industry
First posted
Nov 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with pemetrexed-platinum chemotherapy as first-line treatment in patients with metastatic non-squamous NSCLC.

Conditions

  • Non Squamous Non Small Cell Lung Cancer

Interventions

  • MB12 (Proposed Pembrolizumab Biosimilar)Drug

    200mg IV, every 3 weeks on Day 1

  • EU-sourced Keytruda®Drug

    200mg IV, every 3 weeks on Day 1

  • US-sourced Keytruda®Drug

    200mg IV, every 3 weeks on Day 1

  • PemetrexedDrug

    500 mg/m2 IV, every 3 weeks on Day 1

  • CarboplatinDrug

    Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.

  • CisplatinDrug

    75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the pharmacokinetic (PK) bioequivalence of MB12, EU-sourced Keytruda® and US-sourced Keytruda® in combination with chemotherapyTime frame: Week 1 - Week 24
  2. To demonstrate the efficacy equivalence of MB12 and Keytruda® in combination with chemotherapy administered as first-line treatment in patients with advanced/metastatic non-squamous NSCLC (any PD-L1 expression type).Time frame: Week 1 - Week 24

Locations

173 sites in 24 countries. Site status is shown where the registry gives one.

  • Site 101001

    Yerevan, Armenia

  • Site 101002

    Yerevan, Armenia

  • Site 101003

    Yerevan, Armenia

  • Site 101004

    Yerevan, Armenia

  • Site 103001

    Sarajevo, Bosnia and Herzegovina

  • Site 103002

    Tuzla, Bosnia and Herzegovina

  • Site 103003

    Zenica, Bosnia and Herzegovina

  • Site 301014

    Barretos, Brazil

  • Site 301026

    Belém, Brazil

  • Site 301002

    Belo Horizonte, Brazil

  • Site 301023

    Bento Gonçalves, Brazil

  • Site 301006

    Blumenau, Brazil

  • Site 301019

    Caxias do Sul, Brazil

  • Site 301015

    Curitiba, Brazil

  • Site 301028

    Curitiba, Brazil

  • Site 301024

    Florianópolis, Brazil

  • Site 301010

    Fortaleza, Brazil

  • Site 301011

    Ijuí, Brazil

  • Site 301008

    Itajaí, Brazil

  • Site 301012

    Jaú, Brazil

  • Site 301018

    Natal, Brazil

  • Site 301003

    Porto Alegre, Brazil

  • Site 301005

    Porto Alegre, Brazil

  • Site 301007

    Porto Alegre, Brazil

  • Site 301016

    Porto Alegre, Brazil

  • Site 301022

    Recife, Brazil

  • Site 301009

    Rio de Janeiro, Brazil

  • Site 301020

    Santo André, Brazil

  • Site 301001

    São José do Rio Preto, Brazil

  • Site 108004

    Batumi, Georgia

  • Site 108005

    Kutaisi, Georgia

  • Site 108011

    Marneuli, Georgia

  • Site 108001

    Tbilisi, Georgia

  • Site 108002

    Tbilisi, Georgia

  • Site 108003

    Tbilisi, Georgia

  • Site 108006

    Tbilisi, Georgia

  • Site 108007

    Tbilisi, Georgia

  • Site 108008

    Tbilisi, Georgia

  • Site 108009

    Tbilisi, Georgia

  • Site 108010

    Tbilisi, Georgia

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.